Table III.
Association between FOXM1 expression and clinicopathological characteristics.
| Characteristics | Patients, n (%) | IOD (mean ± SD) | P-value |
|---|---|---|---|
| Pathological stagea | |||
| Well/moderately differentiated | 47 (67.14) | (2.18±1.72)×105 | 0.512 |
| Poorly differentiated | 19 (27.14) | (2.48±1.45)×105 | |
| Invasive extentb | |||
| Stage 1 | 22 (31.43) | (1.54±1.49)×105 | 0.011c |
| Stage 2 | 20 (28.57) | (2.34±1.36)×105 | 0.103d |
| Stage 3 | 28 (40.00) | (2.71±1.75)×105 | 0.421e |
| Lymph node statusf | |||
| N0 | 44 (62.86) | (2.09±1.60)×105 | 0.408 |
| N1 | 24 (34.29) | (2.44±1.72)×105 | |
| Age, years | |||
| ≤40 | 20 (28.57) | (2.72±1.71)×105 | 0.033g |
| 41–56 | 41 (58.57) | (2.20±1.63)×105 | 0.230h |
| ≥56 | 9 (12.86) | (1.33±0.99)×105 | 0.143i |
a
Pathological stage was undetermined in 4 patients.
b
According to the American Joint Committee on Cancer classification. Equal variance, Fisher's least significant difference test:
c
Stage 3 vs. stage 1
d
stage 1 vs. stage 2
e
stage 2 vs. stage 3
f
Lymph node status was undetermined in 2 patients.
g
patients in the ≤40-year-old group compared with patients in the ≥56-year-old group
h
patients in the ≤40-year-old group compared with patients in the 41–56 years old group
i
patients in the 41–56-year-old compared with patients in the ≥56-year-old group. IOD, integrated optical density; SD, standard deviation.